

TABLE S7. Correlations between exacerbation frequency and clinical parameters and IgA⁺ memory B cells

Clinical variable	Variable	estimate	adjusted p-value
Exacerbations [no]	CD27 ⁺ IgA ⁺ B cell [%]	0.351	< 0.001
Exacerbations [no]	Sputum eosinophils [%]	0.32	0.005
Exacerbations [no]	Blood neutrophils [1000/ μ l]	0.32	0.003
Exacerbations [no]	CD27 ⁺ IgA ⁺ B cell [%]	0.26	0.012
Exacerbations [no]	AX [kPa/l/s]	0.239	0.025
Exacerbations [no]	ICS (Fluticasone-equivalent) [μ g/d]	0.22	0.037
Exacerbations [no]	R5-R20 [kPa/l/s]	0.219	0.038
Exacerbations [no]	Blood eosinophils [1000/ μ l]	0.119	0.275
Exacerbations [no]	BMI [Kg/m ²]	0.088	0.423
Exacerbations [no]	FeNO [ppb]	0.084	0.448
Exacerbations [no]	Disease Duration [yrs]	0.005	0.953
Exacerbations [no]	Age [yrs]	-0.03	0.815
Exacerbations [no]	Smoking [py]	-0.054	0.658
Exacerbations [no]	OCS [mg/d]	-0.065	0.814
Exacerbations [no]	Sputum neutrophils [%]	-0.097	0.423
Exacerbations [no]	FEV ₁ /FVC [z-score]	-0.241	0.023
Exacerbations [no]	Specific IgE [kU/l]	-0.242	0.021
Exacerbations [no]	FEV ₁ [z-score]	-0.27	0.01
Exacerbations [no]	FEF ₂₅₋₇₅ [z-score]	-0.32	0.008

TABLE S7. Correlations between exacerbation frequency and clinical parameters and IgA⁺ memory B cells. Estimates and adjusted p-values after multiple test corrections are shown. No, number; BMI, Body Mass Index; yrs, years; PY, pack-years; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV₁/FVC, FEV₁ as % of FVC; FEF₂₅₋₇₅, forced expiratory flow at 25% - 75% of FVC; IgE, Immunoglobulin E; OCS, oral corticosteroids; FeNO, fractional exhaled nitric oxide; ppb, parts per billion; ICS, inhaled corticosteroids; AX, reactance area [kPa/l/s]; R5–R20, resistance at 5 Hz – resistance at 20 Hz [kPa/l/s].